Although previous studies have highlighted the significant antitumor activity of the cGAS-STING pathway (Lv et al., 2024[70]), recent findings show that a triple therapy combining IFN-γ, STING agonist, and anti-PD-1 antibody significantly enhances cGAS/STING expression, IFN-β secretion, and tumor cell apoptosis. Here, STING1 is linked to neoplasm.